[Treatment of advanced pancreatic carcinoma].
Gemcitabine monotherapy extends survival times in locally advanced or metastatic pancreatic carcinoma compared with supportive treatment alone. Among patients who develop skin lesions of grade 2 or more, giving erlotinib in addition doubles survival times - from 5.9 to 10.5 months. Attempting therapy with gemcitabine plus erlotinib is therefore sensible. In patients with a good performance status, survival times can be extended using the combinations gemcitabine plus capecitabine or gemcitabine plus platinum. Radiochemotherapy is not sensible. For second-line treatment, oxaliplatin, 5-FU, and folic acid can be used.
Höhler
Thomas
T
Medizinische Klinik I, Prosper Hospital, Recklinghausen, Deutschland. thomas.hoehler@prosper-hospital.de
Staib
Ludger
L
Oettle
Helmut
H
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D010166:Palliative Care / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010984:Platinum / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D013727:Terminal Care / Q000379:methods*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D011799:Quinazolines; D003841:Deoxycytidine; D010984:Platinum; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine